Once-a-week Diabetes Drug,succeeds in key Trial--Good News.

[DRH-sangli]

Novo Nordisk A/S said on 16th August 2017,its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.The 40-week trial tested two dosages of Novo's once-weekly drug, semaglutide, in addition to initial standard-of-care therapy metformin, against Eli Lilly and Co's dulaglutide plus metformin.

SEE THE REPORT-in link...

newsmax.com/Health/Health-N...